Search

Your search keyword '"Ferrari, E."' showing total 3,406 results
Start Over Author "Ferrari, E."
3,406 results on '"Ferrari, E."'

153. Nucleation control in solution mediated polymorphic phase transformations: the case of 2,6-dihydroxybenzoic acid

Author

Davey, R. J., Blagden, N., Righini, S., Alison, H., and Ferrari, E. S.

Subjects
Chemistry, Physical and theoretical -- Research, Nucleation -- Physiological aspects, Solution (Chemistry) -- Physiological aspects, Polymers -- Physiological aspects, Benzoic acid -- Physiological aspects, Hydrogen -- Physiological aspects, Chemicals, plastics and rubber industries
Published
2002

159. HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

Author

Boccara, Franck, primary, Mary‐Krause, Murielle, additional, Potard, Valérie, additional, Teiger, Emmanuel, additional, Lang, Sylvie, additional, Hammoudi, Nadjib, additional, Chauvet, Marion, additional, Ederhy, Stéphane, additional, Dufour‐Soulat, Laurie, additional, Ancedy, Yann, additional, Nhan, Pascal, additional, Adavane, Saroumadi, additional, Steg, Ph. Gabriel, additional, Funck‐Brentano, Christian, additional, Costagliola, Dominique, additional, Cohen, Ariel, additional, Weber, S., additional, Wahbi, K., additional, Beaufils, P., additional, Henri, P., additional, Sideris, G., additional, Thomas, D., additional, Montalescot, G., additional, Beygui, F., additional, Meuleman, C., additional, Janower, S., additional, Raoux, F., additional, Dufaitre, G., additional, Benyounes, N., additional, Michel, P. L., additional, Petillon, B., additional, Hammoudi, N., additional, Gueret, P., additional, Dubois‐Rande, J. L., additional, Teiger, E., additional, Lim, P., additional, Slama, M., additional, Colin, P., additional, Saudubray, C., additional, Dubourg, O., additional, Milleron, O., additional, Gallet, B., additional, Duclos, F., additional, Godard, S., additional, Fuchs, L., additional, Dormagen, V., additional, Lewy, P., additional, Cattan, S., additional, Nallet, O., additional, Grollier, G., additional, Shayne, J., additional, Wolf, J. E., additional, Cottin, Y., additional, Machecourt, J., additional, Bouvaist, H., additional, Finet, G., additional, De Breyne, B., additional, Trochu, J. N., additional, Baudouy, M., additional, Ferrari, E., additional, Benhamou, M., additional, Allal, J., additional, Coisne, D., additional, Le Breton, H., additional, Bedossa, M., additional, Puel, J., additional, Elbaz, M., additional, Larifla, L., additional, Matheron, S., additional, Landman, R., additional, Fremont, G., additional, Spiridon, G., additional, Blanche, P., additional, Morini, J. P., additional, Sicard, D., additional, Zeller, V., additional, Batisse, D., additional, Clevenbergh, P., additional, Cessot, G., additional, Dohin, E., additional, Valantin, M. A., additional, Khelifa, S., additional, Girard, P. M., additional, Lallemand, F., additional, Lefebvre, B., additional, Laporte, J. P., additional, Meynard, J. L., additional, Bideault, H., additional, Picard, O., additional, Meyohas, M. C., additional, Campa, P., additional, Tredup, J., additional, Fonquernie, L., additional, Raguin, G., additional, Molina, J. M., additional, Furco, A., additional, Gharakanian, S., additional, Vincensini, J. P., additional, Guiard‐Schmid, J. B., additional, Pialoux, G., additional, Cardon, B., additional, Lascaux, A. S., additional, Chaix, F., additional, Lesprit, P., additional, Fior, R., additional, Boue, F., additional, Dupont, C., additional, Bellier, C., additional, Blanc, A., additional, Lambert, T., additional, Touahri, T., additional, Force, G., additional, de Truchis, P., additional, Compagnucci‐Seguenot, M. A., additional, Cahitte, I., additional, Roudière, L., additional, Techer, M. E., additional, Thelpin, P., additional, Troisvallets, D., additional, Lepretre, A., additional, Echard, M., additional, Le Mercier, Y., additional, Houlbert, D., additional, Dargere, S., additional, Bazin, C., additional, Verdon, R., additional, De Goer, B., additional, Duong, M., additional, Chavanet, P., additional, Gozlan, E., additional, Leclercq, P., additional, Brunel‐Dal Mas, F., additional, Durant, J., additional, Heudier, P., additional, Brunet‐François, C., additional, Le Moal, G., additional, Chapplin, J. M., additional, Arvieux, C., additional, Chaumentin, G., additional, Guerin, B., additional, Bonnet, E., additional, Poinsignon, Y., additional, Boulard, F., additional, De Lacroix, I., additional, Goerger‐Sow, M. T., additional, Kirstetter, M., additional, Volstein, M., additional, Laylavoix, F., additional, Copin, X., additional, and Ceppi, C., additional

Published
2020
Full Text
View/download PDF

160. The VALU3S ECSEL Project: Verification and Validation of Automated Systems Safety and Security

Author

Barbosa, R., primary, Basagiannis, S., additional, Giantamidis, G., additional, Becker, H., additional, Ferrari, E., additional, Jahic, J., additional, Kanak, A., additional, Esnaola, M. Labayen, additional, Orani, V., additional, Pereira, D., additional, Pomante, L., additional, Schlick, R., additional, Smrcka, A., additional, Yazici, A., additional, Folkesson, P., additional, and Sangchoolie, B., additional

Published
2020
Full Text
View/download PDF

167. Tumor-non-tumor discrimination by aβ-detector for Radio Guided Surgery on ex-vivo neuroendocrine tumors samples

Author

Morganti, S., primary, Bertani, E., additional, Bocci, V., additional, Colandrea, M., additional, Collamati, F., additional, Cremonesi, M., additional, De Simoni, M., additional, Ferrari, E., additional, Fischetti, M., additional, Funicelli, L., additional, Grana, C.M., additional, Mancini-Terracciano, C., additional, Mirabelli, R., additional, Papi, S., additional, Pisa, E., additional, Solfaroli-Camillocci, E., additional, Traini, G., additional, and Faccini, R., additional

Published
2020
Full Text
View/download PDF

168. Ten Years of ECP for CLAD: A Real Life Experience

Author

Rossetti, V., primary, Righi, I., additional, Morlacchi, L., additional, Fante, C. Del, additional, Mocellin, M., additional, Ferrari, E., additional, Cattaneo, M., additional, Perotti, C., additional, Tarsia, P., additional, Rosso, L., additional, and Blasi, F., additional

Published
2020
Full Text
View/download PDF

179. Challenges in simulating beam dynamics of dielectric laser acceleration

Author

Niedermayer, Uwe, primary, Adelmann, A., additional, Bettoni, S., additional, Calvi, M., additional, Dehler, M., additional, Ferrari, E., additional, Frei, F., additional, Hauenstein, D., additional, Hermann, B., additional, Hiller, N., additional, Ischebeck, R., additional, Lombosi, C., additional, Prat, E., additional, Reiche, S., additional, Rivkin, L., additional, Aßmann, R., additional, Dorda, U., additional, Hartl, I., additional, Kuropka, W., additional, Lemery, F., additional, Marchetti, B., additional, Mayet, F., additional, Xuan, H., additional, Zhu, J., additional, Black, D. S., additional, Broaddus, P. N., additional, Byer, R. L., additional, Ceballos, A., additional, Deng, H., additional, Fan, S., additional, Harris, J., additional, Hirano, T., additional, Hughes, T. W., additional, Jiang, Y., additional, Langenstein, T., additional, Leedle, K., additional, Miao, Y., additional, Ody, A., additional, Pigott, A., additional, Sapra, N., additional, Solgaard, O., additional, Su, L., additional, Tan, S., additional, Vuckovic, J., additional, Yang, K., additional, Zhao, Z., additional, Boine-Frankenheim, O., additional, Egenolf, T., additional, Skär, E., additional, Cesar, D., additional, Musumeci, P., additional, Naranjo, B., additional, Rosenzweig, J., additional, Shen, X., additional, Cowan, B., additional, England, R. J., additional, Huang, Z., additional, Cankaya, H., additional, Fakhari, M., additional, Fallahi, A., additional, Kärtner, F. X., additional, Feurer, T., additional, Hommelhoff, P., additional, Illmer, J., additional, Li, A., additional, Mittelbach, A., additional, McNeur, J., additional, Schönenberger, N., additional, Shiloh, R., additional, Tafel, A., additional, Yousefi, P., additional, Kozak, M., additional, Qi, M., additional, Lee, Y. J., additional, Huang, Y.-C., additional, and Simakov, E., additional

Published
2019
Full Text
View/download PDF

183. Edoxaban for the treatment of cancer-associated venous thromboembolism

Author

Raskob, GE, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, MA, Kakkar, AK, Kovacs, MJ, Mercuri, MF, Meyer, G, Segers, A, Shi, M, Wang, TF, Yeo, E, Zhang, G, Zwicker, JI, Weitz, JI, Büller, HR, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, PW, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, JW, Crowther, M, Roberts, RS, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, JC, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, MI, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, HM, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, CM, Shah, V, Smith, W, Wun, T, Xiang, Z, Raskob, G, van Es, N, Verhamme, P, Carrier, M, Di Nisio, M, Garcia, D, Grosso, M, Kakkar, A, Kovacs, M, Mercuri, M, Meyer, G, Segers, A, Shi, M, Wang, T, Yeo, E, Zhang, G, Zwicker, J, Weitz, J, Büller, H, Beyer-Westendorf, J, Boda, Z, Chlumsky, Y, Gibbs, H, Kamphuizen, P, Monreal, M, Ockleford, P, Pabinger-Fasching, I, Sinnaeve, P, Beenen, L, Gerdes, V, Laleman, W, Larrey, D, van Mechelen, R, Roos, Y, Scheerder, M, Slagboom, T, Thijs, V, Eikelboom, J, Crowther, M, Roberts, R, Vanassche, T, Vandenbriele, C, Debaveye, B, Dani, V, Schwocho, L, Duggal, A, Baker, R, Carroll, P, Chan, N, Coughlin, P, Crispin, P, Gallus, A, Hugman, A, Tran, H, Brodmann, M, Mathies, R, Rossmann, D, Deeren, D, Hainaut, P, Jochmans, K, Vercauter, P, Wautrecht, J, Champion, P, Gross, P, Lee, A, Shivakumar, S, Tagalakis, V, Zed, E, Kovarova, K, Lastuvka, J, Matoska, P, Prosecky, R, Achkar, A, Aquilanti, S, Chatellain, P, Cony-Makhoul, P, Del Piano, F, Elias, A, Falvo, N, Ferrari, E, Mahé, I, Merle, P, Mismetti, P, Muron, T, Pernod, G, Quere, I, Schmidt, J, Stephan, D, Espinola-Klein, C, Horacek, T, Kröning, R, Oettler, W, Schellong, S, Schön, N, Zwemmrich, C, Farkas, K, Gurzo, M, Nyirati, G, Pecsvarady, Z, Riba, M, Becattini, C, Cattaneo, M, Falanga, A, Ghirarduzzi, A, Imberti, D, Lodigiani, C, Parisi, R, Porreca, E, Squizzato, A, Tassoni, M, Villalta, S, Visonà, A, Beeker, A, Boersma, W, Brouwer, R, Dees, A, Huisman, M, Kuijer, P, Mairuhu, R, Meijer, K, Middeldorp, S, Otten, H, van Marwijk-Kooy, M, van Wissen, S, Westerweel, P, Harper, P, Merriman, E, Ockelford, P, Royle, G, Smith, M, Cereto Castro, F, de Oña Navarrete, R, Font Puig, C, Gallardo Díaz, E, Garcia-Bragado Dalmau, F, Ruiz Artacho, P, Santamaria, A, Baumann Kreuziger, L, De Sancho, M, Gaddh, M, Metjian, A, Rojas Hernandez, C, Shah, V, Smith, W, Wun, T, Xiang, Z, Graduate School, CCA - Cancer Treatment and Quality of Life, Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, ANS - Neurovascular Disorders, Radiology and Nuclear Medicine, Other Research, Other departments, Neurology, APH - Societal Participation & Health, APH - Quality of Care, Coronel Institute of Occupational Health, ARD - Amsterdam Reproduction and Development, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Atherosclerosis & ischemic syndromes, ACS - Pulmonary hypertension & thrombosis, and ACS - Microcirculation

Subjects
Adult, Dalteparin, Male, Randomization, Pyridines, Hemorrhage, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Recurrence, law, Edoxaban, Neoplasms, medicine, Humans, Aged, Intention-to-treat analysis, Heparin, business.industry, Standard treatment, Low-Molecular-Weight, Anticoagulants, Cancer, Follow-Up Studies, Heparin, Low-Molecular-Weight, Intention to Treat Analysis, Middle Aged, Thiazoles, Venous Thromboembolism, General Medicine, medicine.disease, Thrombosis, chemistry, 030220 oncology & carcinogenesis, Anesthesia, Venous Thromboembolism, cancer, thrombosis, business, medicine.drug
Abstract

BACKGROUND Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. METHODS In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration. RESULTS Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analysis. A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P = 0.006 for noninferiority; P = 0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, -3.4 percentage points; 95% CI, -7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6). CONCLUSIONS Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin. (Funded by Daiichi Sankyo; Hokusai VTE Cancer ClinicalTrials. gov number, NCT02073682.)

Published
2018

186. Temporal Trends in Adoption and Outcomes of Transcatheter Aortic Valve Implantation: A Swisstavi Registry Analysis

Author

Stortecky S, Franzone A, Heg D, Tueller D, Noble S, Pilgrim T, Jeger R, Toggweiler S, Ferrari E, Nietlispach F, Taramasso M, Maisano F, Grunenfelder J, Muller O, Huber C, Roffi M, Carrel T, Wenaweser P, Windecker S, Stortecky, S, Franzone, A, Heg, D, Tueller, D, Noble, S, Pilgrim, T, Jeger, R, Toggweiler, S, Ferrari, E, Nietlispach, F, Taramasso, M, Maisano, F, Grunenfelder, J, Muller, O, Huber, C, Roffi, M, Carrel, T, Wenaweser, P, and Windecker, S

Published
2018

187. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

Author

Castagna, A., Ferrara, M., Galli, L., Comi, L., Sterrantino, G., Cenderello, G., Zaccarelli, M., Focà, E., Roncadori, A., Lazzarin, A., Chichino, G., Mantia, E., Butini, L., Costantini, A., Giacometti, A., Tavio, M., Grassini, M., Valle, M., Vaccher, E., Martellotta, F., Schioppa, O., Maggiolo, F., Viale, P., Borderi, M., Calza, L., Moratello, L., Magistrelli, E., Castelli, F., Festa, E., Quirino, T., Campus, M., Businco, F., Celesia, B. M., La Rosa, R., Pan, A., Fornabaio, C., Mazzotta, F., Di Pietro, M., Bartoloni, A., Ferrara, S., Mastroianni, A., Di Cesare, S., Viscoli, C., Di Biagio, A., Cassola, G., Penco, G., Cericola, A, Nencioni, C., Carli, T., Viganò, P., Re, T., Del Fiorentino, A., Gattuso, G., Palvarini, L., Taurozzi, M., Gianotti, N., Galizzi, N., Poli, A., Rusconi, S., Salvaggio, S. E., Galli, M., Rizzardini, G., Mussini, C., Menozzi, M., Gori, A., Muscatello, A., Cappelletti, E., Gargiulo, M., Garavelli, P. L., Bargiacchi, O., Prestileo, T., Di Lorenzo, F., Bonanno, S., Ferrari, C., degli Antoni, A. M., Cattelan, A. M., Gulminetti, R., Pagnucco, L., Menichetti, F., Iapoce, R., Baldelli, F., Schiaroli, E., Italiani, F., Aquilini, D., Magnani, G., Corsini, R., Barchi, E., Ferrari, E., Antinori, A., Cristaudo, A., Latini, A., Cauda, R., Vullo, V., Maffongelli, G., Andreoni, M., Sassett, L., Viviani, F., De Luca, A., Rossetti, B., Franco, A., Resta, F., Di Perri, G., Bonora, S., Bassetti, M., Londero, A., Malena, M., Luzzati, Roberto, Castagna, A., Ferrara, M., Galli, L., Comi, L., Sterrantino, G., Cenderello, G., Zaccarelli, M., Focà, E., Roncadori, A., Lazzarin, A., Chichino, G., Mantia, E., Butini, L., Costantini, A., Giacometti, A., Tavio, M., Grassini, M., Valle, M., Vaccher, E., Martellotta, F., Schioppa, O., Maggiolo, F., Viale, P., Borderi, M., Calza, L., Moratello, L., Magistrelli, E., Castelli, F., Festa, E., Quirino, T., Campus, M., Businco, F., Celesia, B. M., La Rosa, R., Pan, A., Fornabaio, C., Mazzotta, F., Di Pietro, M., Bartoloni, A., Ferrara, S., Mastroianni, A., Di Cesare, S., Viscoli, C., Di Biagio, A., Cassola, G., Penco, G., Cericola, A, Nencioni, C., Carli, T., Viganò, P., Re, T., Del Fiorentino, A., Gattuso, G., Palvarini, L., Taurozzi, M., Gianotti, N., Galizzi, N., Poli, A., Rusconi, S., Salvaggio, S. E., Galli, M., Rizzardini, G., Mussini, C., Menozzi, M., Gori, A., Muscatello, A., Cappelletti, E., Gargiulo, M., Garavelli, P. L., Bargiacchi, O., Prestileo, T., Di Lorenzo, F., Bonanno, S., Ferrari, C., degli Antoni, A. M., Cattelan, A. M., Gulminetti, R., Pagnucco, L., Menichetti, F., Iapoce, R., Baldelli, F., Schiaroli, E., Italiani, F., Aquilini, D., Magnani, G., Corsini, R., Barchi, E., Ferrari, E., Antinori, A., Cristaudo, A., Latini, A., Cauda, R., Vullo, V., Maffongelli, G., Andreoni, M., Sassett, L., Viviani, F., De Luca, A., Rossetti, B., Franco, A., Resta, F., Di Perri, G., Bonora, S., Bassetti, M., Londero, A., Malena, M., and Luzzati, Roberto

Subjects
HIV, dolutegravir, efficacy, Male, Anti-HIV Agents, Pyridones, Drug Resistance, HIV Infections, HIV Integrase, 3-Ring, Piperazines, Coinfection, Drug Resistance, Viral, Drug Therapy, Combination, Female, HIV Integrase Inhibitors, HIV-1, Hepatitis C, Chronic, Heterocyclic Compounds, 3-Ring, Humans, Middle Aged, Treatment Outcome, Viral Load, Drug Therapy, Heterocyclic Compounds, Oxazines, Pharmacology (medical), Viral, Chronic, Pharmacology, Pharmacology, Pharmacology (medical), Infectious Diseases, Hepatitis C, Infectious Diseases, Combination
Abstract

OBJECTIVES: This study evaluated the virological efficacy of dolutegravir 50 mg twice daily in 190 HIV-1 failing antiretroviral-experienced patients with previous exposure to first-generation integrase strand transfer inhibitor (INSTI) over a 5 year follow-up using data from clinical practice. PATIENTS AND METHODS: This analysis included HIV-1-infected patients who were ≥18 years of age, treatment experienced, had HIV-1 RNA >50 copies/mL, with INSTI-resistant virus, who started dolutegravir 50 mg twice daily plus optimized background therapy (OBT), recorded in the national prospective database PRESTIGIO (www.progettoprestigio.it). Follow-up accrued from the start of dolutegravir 50 mg twice daily + OBT until virological failure (VF) or dolutegravir discontinuation for any reason or the last treatment visit on dolutegravir 50 mg twice daily treatment. VF was defined by the lack of achievement of HIV-1 RNA 100000 copies/mL (adjusted HR = 4.73, 95% CI = 1.33-16.78, P = 0.016) and with ≥1 INSTI mutations plus Q148H/K/R/N and the G140S/A/C as compared with other subjects (adjusted HR = 4.18, 95% CI = 1.32-13.23, P = 0.015). CONCLUSIONS: Our data showed a favourable long-term efficacy of dolutegravir 50 mg twice daily in association with OBT in treatment-experienced failing subjects, with INSTI-resistant virus, in the real world. A close monitoring of adherence is crucial for maintenance of virological response in this fragile subgroup of subjects.

Published
2018

190. List of Contributors, Part 2

Author

Andrews, J.S., primary, Bonacina, M., additional, Cartmell, T., additional, Cools, A.R., additional, Coste, S.C., additional, Cravello, L., additional, Dettling, A.C., additional, Deutch, A.Y., additional, Dunn, A.J., additional, Ellenbroek, B.A., additional, Feldon, J., additional, Ferrari, E., additional, Geven, E.J., additional, Griebel, G., additional, Grobin, A.C., additional, Groenink, L., additional, Holsboer, F., additional, Khan, S., additional, Levine, S., additional, Lewine, R.R.J., additional, Liberzon, I., additional, Lieberman, J.A., additional, Lu, L., additional, Magri, F., additional, Marinelli, M., additional, Marx, C.E., additional, Mitchell, D., additional, Modell, S., additional, Murray, S.E., additional, Olivier, B., additional, Oosting, R., additional, Piazza, P.V., additional, Pryce, C.R., additional, Reul, J.M.H.M., additional, Rupniak, N.M.J., additional, Rüedi-Bettschen, D., additional, Sakai, R.R., additional, Salmoiraghi, F., additional, Gal, C. Serradeil-Le, additional, Shaham, Y., additional, Sinha, R., additional, Stec, I.E.M., additional, Steckler, T., additional, Stenzel-Poore, M.P., additional, Sterzer, P., additional, Tamashiro, K.L.K., additional, Van Bogaert, M., additional, Van Oorschot, R., additional, Vázquez, D.M., additional, Wiegers, G.J., additional, Yehuda, R., additional, and Young, E.A., additional

Published
2005
Full Text
View/download PDF

191. Stress and dementia

Author

Ferrari, E., primary, Cravello, L., additional, Bonacina, M., additional, Salmoiraghi, F., additional, and Magri, F., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results